Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)

Background: Diffuse large B-cell lymphoma (DLBCL) comprises 31% of lymphomas in the United States. Although it is an aggressive type of lymphoma, 40% to 50% of patients are cured with treatment. The study objectives were to identify...

Full description

Bibliographic Details
Main Authors:	Griffiths, R, Gleeson, M, Knopf, K, Danese, M
Format:	Journal article
Language:	English
Published:	BioMed Central 2010

Similar Items

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
by: Gleeson Michelle, et al.
Published: (2010-11-01)

Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
by: Danese, MD, et al.
Published: (2016)

Retrospective Evaluation of Patients Diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)
by: Atakan TEKİNALP, et al.
Published: (2020-12-01)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
by: Vodicka P, et al.
Published: (2022-12-01)

Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
by: Griffiths, R, et al.
Published: (2010)

Interleukin 10 gene promoter polymorphism and risk of diffuse large B cell lymphoma (DLBCL)
by: Roba M. Talaat, et al.
Published: (2014-01-01)

Diffuse Large B-Cell Lymphoma (DLBCL) in an Aged Raccoon (Procyon lotor)
by: Giulia D’Annunzio, et al.
Published: (2022-11-01)

Identification of molecular factors mediating therapeutic resistance in diffuse large B-cell lymphoma (DLBCL)
by: Peng, Chenchen
Published: (2024)

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)
by: Pengcheng Feng, et al.
Published: (2021-02-01)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
by: Abdulhaq H, et al.
Published: (2023-07-01)

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma
by: Griffiths, R, et al.
Published: (2012)

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
by: Griffiths, R, et al.
Published: (2012)

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
by: Dean A. Regier, et al.
Published: (2022-02-01)

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
by: Lander, Eric Steven
Published: (2012)

The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL)
by: Peter D. Whooley, et al.
Published: (2018-01-01)

Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?
by: WM Tai MBBS(S'pore), MRCP(UK), et al.
Published: (2011-03-01)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
by: Y. Jiang, et al.
Published: (2022-06-01)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
by: Carrasquillo J, et al.
Published: (2009-06-01)

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?
by: Cristiano Claudino Oliveira, et al.
Published: (2020-09-01)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: M. Hamadani, et al.
Published: (2022-06-01)

The Role Of 18F -FDG PET-CT In Assessing Bone Marrow Involvement In Diffuse Large B-Cell Lymphoma (DLBCL)
by: Nasir, Siti Maisarah Mohd
Published: (2018)

PB2152: BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: S. Basic-Kinda, et al.
Published: (2022-06-01)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
by: J. Duell, et al.
Published: (2022-06-01)

Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China
by: Jian-Jun Sun, et al.
Published: (2020-12-01)

Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy
by: Paweł Klimiuk, et al.
Published: (2021-04-01)

Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis.
by: Saaya Tsutsué, et al.
Published: (2022-01-01)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: T. Illidge, et al.
Published: (2022-06-01)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: Allison Bock, et al.
Published: (2023-08-01)

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
by: Barrans, S, et al.
Published: (2004)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
by: Victoria Ramos De Ascanio, et al.
Published: (2023-08-01)

PB2376: ASSAY DEVELOPMENT AND VALIDATION OF IG-HTS TO MONITOR MRD IN PLASMA OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: Jinghua Wu, et al.
Published: (2023-08-01)

Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
by: Gunter Assmann, et al.
Published: (2014-01-01)

Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Their Correlation with Staging and Prognosis of the Disease
by: Hossein Rahimi, et al.
Published: (2015-01-01)

A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes
by: Rajasooriyar Chrishanthi, et al.
Published: (2019-10-01)

Diffuse B-cell lymphoma (DLBCL) causing pathological periprosthetic fracture: A rare case report
by: Sundeep Kund Reddy Aluka, et al.
Published: (2024-09-01)

Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival
by: T. Müller, et al.
Published: (2007-01-01)

Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).
by: Manikhandan A V Mudaliar, et al.
Published: (2013-01-01)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (DLBCL NOS) Presenting as Multiple Subcutaneous Nodules: An Unusual Cutaneous Presentation of Systemic Disease
by: Nika Tavberidze, et al.
Published: (2023-01-01)

CIRCULATING CELL-FREE DNA (CCFDNA) ISOLATION FROM PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): COMPARATIVE ANALYSIS OF COMMERCIAL KITS
by: KS Oliveira, et al.
Published: (2021-10-01)

P1158: REAL-WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND TREATMENT OUTCOMES OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) BY LINE OF THERAPY (LOT)
by: Helmneh Sineshaw, et al.
Published: (2023-08-01)